CY1115003T1 - THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES - Google Patents

THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES

Info

Publication number
CY1115003T1
CY1115003T1 CY20121101174T CY121101174T CY1115003T1 CY 1115003 T1 CY1115003 T1 CY 1115003T1 CY 20121101174 T CY20121101174 T CY 20121101174T CY 121101174 T CY121101174 T CY 121101174T CY 1115003 T1 CY1115003 T1 CY 1115003T1
Authority
CY
Cyprus
Prior art keywords
antibodies
antagonists
subject
therapeutic use
present
Prior art date
Application number
CY20121101174T
Other languages
Greek (el)
Inventor
Marna Williams
J Yun Tso
Nicolas F Landolfi
Gao Liu
Original Assignee
Abbvie Biotherapeutics Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/842,011 external-priority patent/US20050025763A1/en
Priority claimed from US10/982,357 external-priority patent/US7709610B2/en
Application filed by Abbvie Biotherapeutics Inc. filed Critical Abbvie Biotherapeutics Inc.
Publication of CY1115003T1 publication Critical patent/CY1115003T1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2806—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση απευθύνεται σε ανταγωνιστές του CS1 που δεσμεύονται και εξουδετερώνουν μία τουλάχιστον βιολογική δραστηριότητα του CS1. Η εφεύρεση συμπεριλαμβάνει επίσης και μια φαρμακευτική σύνθεση περιλαμβάνοντας τέτοια αντισώματα ή θραύσματα δέσμευσης-αντιγόνων εξ αυτών. Η παρούσα εφεύρεση προβλέπει επίσης και μια μέθοδο πρόληψης ή αγωγής καταστάσεων παθήσεων, συμπεριλαμβάνοντας αυτοάνοσες διαταραχές και καρκίνο, σε ένα υποκείμενο σε ανάγκη εξ αυτών, περιλαμβάνοντας την χορήγηση στο εν λόγω υποκείμενο μιας αποτελεσματικής ποσότητας των εν λόγω ανταγωνιστών.The present invention is directed to CS1 antagonists that bind and neutralize at least one biological activity of CS1. The invention also encompasses a pharmaceutical composition comprising such antibodies or antigen-binding fragments thereof. The present invention also provides a method of preventing or treating conditions of the disease, including autoimmune disorders and cancer, in a subject in need thereof, comprising administering to said subject an effective amount of said antagonists.

CY20121101174T 2004-03-29 2012-11-30 THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES CY1115003T1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US55762104P 2004-03-29 2004-03-29
US55762004P 2004-03-29 2004-03-29
US55762204P 2004-03-29 2004-03-29
US10/842,011 US20050025763A1 (en) 2003-05-08 2004-05-07 Therapeutic use of anti-CS1 antibodies
US10/982,357 US7709610B2 (en) 2003-05-08 2004-11-05 Therapeutic use of anti-CS1 antibodies
EP10180748A EP2301576B1 (en) 2004-03-29 2004-11-08 Therapeutic use of Anti-CS1 Antibodies

Publications (1)

Publication Number Publication Date
CY1115003T1 true CY1115003T1 (en) 2016-12-14

Family

ID=44597272

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20121101174T CY1115003T1 (en) 2004-03-29 2012-11-30 THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES

Country Status (9)

Country Link
JP (1) JP4758984B2 (en)
CY (1) CY1115003T1 (en)
DK (1) DK2301576T3 (en)
ES (1) ES2393539T3 (en)
HK (2) HK1099699A1 (en)
HR (1) HRP20120975T1 (en)
IL (1) IL243687A0 (en)
PT (1) PT2301576E (en)
SI (1) SI2301576T1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009149021A2 (en) * 2008-06-02 2009-12-10 Dana-Farber Cancer Institute, Inc. Xbp1, cd138, and cs1 peptides
US9950047B2 (en) 2012-11-05 2018-04-24 Dana-Farber Cancer Institute, Inc. XBP1, CD138, and CS1 peptides, pharmaceutical compositions that include the peptides, and methods of using such peptides and compositions
WO2015166056A1 (en) * 2014-05-02 2015-11-05 Cellectis Cs1 specific multi-chain chimeric antigen receptor
SG11202010496WA (en) * 2018-05-18 2020-12-30 Daiichi Sankyo Co Ltd Anti-muc1 antibody-drug conjugate
CN112442126B (en) * 2019-09-04 2022-07-29 杭州济元基因科技有限公司 Monoclonal antibody of anti-human CS1 antigen and CAR-T cell thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020123617A1 (en) * 1999-12-23 2002-09-05 Starling Gary C. Novel immunoglobulin superfamily members of APEX-1, APEX-2 and APEX-3 and uses thereof

Also Published As

Publication number Publication date
HK1099699A1 (en) 2007-08-24
DK2301576T3 (en) 2012-12-10
SI2301576T1 (en) 2013-02-28
JP4758984B2 (en) 2011-08-31
IL243687A0 (en) 2016-04-21
ES2393539T3 (en) 2012-12-26
PT2301576E (en) 2012-12-20
JP2007530675A (en) 2007-11-01
HK1155670A1 (en) 2012-05-25
HRP20120975T1 (en) 2013-01-31

Similar Documents

Publication Publication Date Title
CY1119353T1 (en) ANTI-CS1 ANTIBODY TREATMENT USE
BRPI0418695A (en) therapeutic use of anti-cs1 antibodies
CY1113489T1 (en) ANTIBODY THAT INCLUDES ALPHABETA7 INTEGRINE AND USE THIS IN THE THERAPEUTIC TREATMENT OF THE INFLAMMATORY INTELLIGENCE
BRPI0611984A2 (en) use of igf-ir antibodies to manufacture a drug to treat a bone tumor
CY1116230T1 (en) BINDING-NOTCH FACTORS AND COMPETITORS AND METHODS OF USE THEREOF
EA200800355A1 (en) NEUTRALIZING HUMAN ANTIBODIES AGAINST B7RP1
UA89350C2 (en) Humanized antibody that specifically binds human cd20
CY1115003T1 (en) THERAPEUTIC USE OF ANTI-CS1 ANTIBODIES
EA201070636A1 (en) INHIBITION OF THE PROTECTOR PROTEIN, STIMULATING MACROPHAGE (RON), AND METHODS OF ITS TREATMENT
MA31899B1 (en) Monoclonal antibodies are associated with hgm-csf and the medical structures they contain
EA200600921A1 (en) METHODS AND COMPOSITIONS WITH THE USE OF TALIDOMIDE FOR THE TREATMENT AND MANAGEMENT OF CANCER AND OTHER DISEASES
WO2008042941A3 (en) Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease
TH1601004178A (en) Humen antibodies to PD-1
CY1113459T1 (en) CONDITIONS THERAPY THAT INCLUDE DEEMINATION
TH90007B (en) Using a single dose of the CD20-specific binding molecule.
CY1114654T1 (en) ANTI-CD40 MONOCLONIC ANTIBODIES ANTI-COMPONENTS AND METHODS FOR USE
TH90007A (en) Using a single dose of the CD20-specific binding molecule.